Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Veterinary Internal Medicine

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1939-1676.2012.00932.xPMID 22524260
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.

  2010cited by this paper
• The endocrine system

  2010cited by this paper
• Efficacy of trilostane for the treatment of equine Cushing's syndrome.

  2010cited by this paper
• Biochemical indices of vascular function, glucose metabolism and oxidative stress in horses with equine Cushing's disease.

  2010cited by this paper
• Serum insulin concentrations in horses with equine Cushing's syndrome: response to a cortisol inhibitor and prognostic value.

  2010cited by this paper
• Effects of compounding and storage conditions on stability of pergolide mesylate.

  2009cited by this paper
• Editorial: Diagnosing Equine Pars Intermedia Dysfunction: Are We There Yet?

  2008cited by this paper
• Myopathy in horses with pituitary pars intermedia dysfunction (Cushing's disease).

  2006cited by this paper
• Evaluation of the combined dexamethasone suppression/ thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses.

  2006cited by this paper
• Diagnosing equine pars intermedia dysfunction: are we there yet?

  2005cited by this paper
• Editorial: Diagnosing Equine Pars Intermedia Dysfunction: Are We There Yet?

  2005cited by this paper
• Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses.

  2005cited by this paper
• Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.

  2004cited by this paper
• Pituitary pars intermedia dysfunction: equine Cushing's disease.

  2002cited by this paper
• Equine Cushing's disease.

  2002cited by this paper
• Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).

  2002cited by this paper
• The Michigan Cushing's Project

  2001cited by this paper
• Results of a combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test in healthy horses and horses suspected to have a pars intermedia pituitary adenoma.

  1997cited by this paper
• Equine Cushing's disease

  1997cited by this paper
• Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism.

  1996cited by this paper
• Laboratory diagnosis of equine pituitary pars intermedia adenoma.

  1995cited by this paper
• Diagnostic testing for pituitary pars intermedia dysfunction in horses.

  1994cited by this paper
• Equine Cushing's disease.

  1993cited by this paper
• Equine pituitary neoplasia: a clinical report of 21 cases (1990-1992)

  1993cited by this paper
• Diagnosis of hyperadrenocorticism in the horse

  1992cited by this paper
• Steroid hepatopathy in a horse with glucocorticoid-induced hyperadrenocorticism.

  1992cited by this paper
• Immunocytochemical Demonstration of Proopiomelanocortin-derived Peptides in Pituitary Adenomas of the Pars Intermedia in Horses

  1990cited by this paper
• Cushing's syndrome in a horse.

  1988cited by this paper
• Hormonal response to thyrotropin-releasing hormone in healthy horses and in horses with pituitary adenoma.

  1985cited by this paper
• Corticosteroid-potentiated vascular responses of the equine digit: a possible pharmacologic basis for laminitis.

  1979cited by this paper
• Adenomas of the pars intermedia associated with hyperglycemia and glycosuria in two horses.

  1966cited by this paper
• Adenomas of the pars intermedia associated with hyperglycemia and glycosuria in two horses.

  1966cited by this paper

• Time but not storage of equine plasma in silicate-coated tubes affects adrenocorticotropic hormone stability.

  2025cites this paper
• Horses diagnosed with pituitary pars intermedia dysfunction do not have shorter life expectancies but experience more medical events during their lifetime.

  2025cites this paper
• Hufrehe heute – warum wir einen Perspektivwechsel brauchen

  2025cites this paper
• Equine Pituitary Pars Intermedia Dysfunction

  2025influential citation
• Long‐Term Response of Equids With Pituitary Pars Intermedia Dysfunction to Treatment With Pergolide

  2025cites this paper
• Prevalence and Progression of Resting ACTH, Insulin and Adiponectin Values as Indicators of Suspected Endocrine Diseases in Sport Horses and Ponies Compared to Non-Sport Horses, Ponies and Donkeys

  2025cites this paper
• Development of a health‐related quality‐of‐life assessment tool for equines with pituitary pars intermedia dysfunction

  2025cites this paper
• Association Between Adrenocorticotropic Hormone Concentration and Clinical Signs of Pituitary Pars Intermedia Dysfunction in Swiss and Austrian Equids

  2025cites this paper
• Strongyle egg shedding and egg reappearance periods in horses with pituitary pars intermedia dysfunction.

  2024cites this paper
• Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction

  2024cites this paper
• BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.

  2023cites this paper
• Diagnosis of equine pituitary pars intermedia dysfunction.

  2023cites this paper
• Pituitary pars intermedia dysfunction in horses associated to pituitary adenoma

  2023cites this paper
• Short-Term Effects of Temperature and Thyrotropin-Releasing Hormone Stimulation on Adrenocorticotropin Stability in Horses

  2022cites this paper
• Prospective Case Series of Clinical Signs and Adrenocorticotrophin (ACTH) Concentrations in Seven Horses Transitioning to Pituitary Pars Intermedia Dysfunction (PPID)

  2022cites this paper
• Pituitary Pars Intermedia Dysfunction (PPID) in Horses

  2022cites this paper
• Correlation of pituitary histomorphometry with dopamine and dopamine D2 receptor expression in horses with pituitary pars intermedia dysfunction.

  2022cites this paper
• Management of Pituitary Pars Intermedia Dysfunction in Practice: A Clinical Audit.

  2022cites this paper
• Evaluation of the sensitivity and specificity of basal plasma adrenocorticotrophic hormone concentration for diagnosing pituitary pars intermedia dysfunction in horses: A systematic review.

  2021cites this paper
• Retrospective analysis of cause-of-death at an equine retirement center in the Netherlands over an eight year period.

  2021cites this paper
• Nutritional considerations for the management of equine pituitary pars intermedia dysfunction

  2021cites this paper
• Equine pituitary pars intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis through a priority setting partnership.

  2021cites this paper
• Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review.

  2020cites this paper
• Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses.

  2020cites this paper
• Incidence and risk factors for recurrence of endocrinopathic laminitis in horses

  2019cites this paper
• Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.

  2019cites this paper
• Does pergolide therapy prevent laminitis in horses diagnosed with pituitary pars intermedia dysfunction

  2019cites this paper
• Evaluation of combined testing to simultaneously diagnose pituitary pars intermedia dysfunction and insulin dysregulation in horses

  2019cites this paper
• Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.

  2018cites this paper
• Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group

  2018influential citation
• Endocrine testing for causes of laminitis in a group of Australian horses

  2018cites this paper
• Endocrine tumours in equids

  2018cites this paper
• Equine pituitary pars intermedia dysfunction: An international survey of veterinarians' approach to diagnosis, management, and estimated prevalence.

  2017cites this paper
• Long‐term and Short‐term Dopaminergic (Cabergoline) and Antidopaminergic (Sulpiride) Effects on Insulin Response to Glucose, Glucose Response to Insulin, or Both in Horses

  2017cites this paper
• Therapeutics for Equine Endocrine Disorders.

  2017cites this paper
• Initial analytic quality assessment and method comparison of an immunoassay for adrenocorticotropic hormone measurement in equine samples.

  2016cites this paper
• Endocrine Disease in Aged Horses.

  2016cites this paper
• Effects of Common Equine Endocrine Diseases on Reproduction.

  2016cites this paper
• What’s New in Old Horses? Postmortem Diagnoses in Mature and Aged Equids

  2016influential citation
• 56 – Veterinary aspects of the aged equine athlete

  2014cites this paper
• Science-in-brief: Report from the second [corrected] European Equine Endocrinology symposium.

  2014cites this paper
• Comparison of Insulin and Glucose Metabolism in Horses with Pituitary Pars Intermedia Dysfunction Treated Versus Not Treated with Pergolide

  2014cites this paper
• Pituitary pars intermedia dysfunction: Diagnosis and treatment

  2014influential citation
• Determination of pergolide in horse plasma by UPLC-MS/MS for pharmacokinetic applications.

  2014cites this paper
• Evaluation of the effects of age and pituitary pars intermedia dysfunction on corneal sensitivity in horses.

  2013cites this paper
• LA « MALADIE DE CUSHING » CHEZ LE CHEVAL: DYSFONCTIONNEMENT DE LA PARS INTERMEDIA DE L'HYPOPHYSE

  2013cites this paper
• Science-in-brief : Report from the Fourth European Equine

  year unknowncites this paper